Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Writing Group for the Women’s Health Initiative Investigators.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women.
JAMA, 288 (2002), pp. 321-333
[2.]
Million Women Study Collaborators.
Breast cancer and hormone-replacement therapy in the Million Women Study.
Lancet, 362 (2003), pp. 419-427
[3.]
Collaborative Group of Hormonal Factors in Breast Cancer.
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer.
Lancet, 350 (1997), pp. 1047-1059
[4.]
The Women’s Health Initiative Steering Committee.
Effects of conjugate equine estrogen in postmenopausal women with hysterectomy.
JAMA, 291 (2004), pp. 1701-1712
[5.]
K. Lillberg, P.K. Verkasalo, J. Kaprio, L. Teppo, H. Helenius, M. Koskenvuo.
Stressful life events and risk of breast cancer in 10,808 women: a cohort study.
Am J Epidemiol, 157 (2003), pp. 415-423
[6.]
M. Wenten, F. Gilliland, K. Baumgartner, J.M. Samet.
Associations of weight change and body mass with breast cancer risk in hispanic and non-hispanic white women.
Ann Epidemiol, 12 (2002), pp. 435-444
[7.]
Instituto Nacional de Estadística. Disponible en: http://www.ine.es
[8.]
M. Benet, A. Carvajal, J. García, A. Álvarez, T. Vega.
Tratamiento hormonal sustitutivo en España. Un estudio de utilización.
Med Clin (Barc), 119 (2002), pp. 4-8
Copyright © 2005. Elsevier España S.L. Barcelona
